Evidence map›Paper›PMID 40548414›Full record

ArticleThe Cochrane database of systematic reviews2025

Myosin inhibitors for treatment of hypertrophic cardiomyopathy.

Samuel Quill, Ahmad S Amin, Folkert W Asselbergs, Connie Bezzina, Perry M Elliott, Jolanda van der Velden, Amand F Schmidt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Cochrane database of systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samuel QuillInstitute of Cardiovascular Science, University College London, London, UK.
Ahmad S AminDepartment of Cardiology, Amsterdam University Medical Center, Amsterdam, Netherlands.
Folkert W AsselbergsInstitute of Cardiovascular Science, University College London, London, UK.
Connie BezzinaHeart Center, Academic Medical Center, Amsterdam University Medical Center, Amsterdam, Netherlands.
Perry M ElliottInstitute of Cardiovascular Science, University College London, London, UK.
Jolanda van der VeldenHeart Center, Academic Medical Center, Amsterdam University Medical Center, Amsterdam, Netherlands.
Amand F SchmidtInstitute of Cardiovascular Science, University College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primary objective To assess the effects of myosin inhibitors compared to usual care or placebo on exercise capacity, need for septal reduction therapy, and all-cause mortality in people with hypertrophic cardiomyopathy (HCM). Secondary objectives To assess the effects of myosin inhibitors compared to usual care or placebo in people with HCM in the following population subgroups. By demographics, such as age and sex Obstructive HCM versus non-obstructive HCM Genotype-negative and genotype-positive disease People with and without pre-existing atrial fibrillation or other types of arrhythmias.

Indexed as

Cardiomyopathy, HypertrophicMyosinsBenzylaminesCarbamatesExercise ToleranceHumansRandomized Controlled Trials as TopicReview Literature as TopicUracilUreaBenzylaminesCarbamatesMYK-461Myosinsomecamtiv mecarbilUracilUrea

Identifiers

PMID40548414
PMCPMC12183782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.